BIIB Stock - Biogen Inc.
Unlock GoAI Insights for BIIB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $9.68B | $9.84B | $10.17B | $10.98B | $13.44B |
| Gross Profit | $7.37B | $7.30B | $7.90B | $8.87B | $11.64B |
| Gross Margin | 76.1% | 74.2% | 77.6% | 80.8% | 86.6% |
| Operating Income | $2.49B | $2.10B | $2.89B | $2.79B | $4.59B |
| Net Income | $1.63B | $1.16B | $3.05B | $1.56B | $4.00B |
| Net Margin | 16.9% | 11.8% | 29.9% | 14.2% | 29.8% |
| EPS | $11.20 | $8.02 | $20.97 | $10.44 | $24.86 |
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 10th 2025 | HSBC Securities | Downgrade | Reduce | $143 |
| November 6th 2025 | Stifel | Upgrade | Buy | $202 |
| September 25th 2025 | Jefferies | Initiation | Buy | $190 |
| July 21st 2025 | Truist | Resumed | Hold | $142 |
| April 28th 2025 | HSBC Securities | Downgrade | Hold | $118 |
| April 4th 2025 | Argus | Downgrade | Hold | - |
| February 11th 2025 | Bernstein | Initiation | Market Perform | $160 |
| January 2nd 2025 | Piper Sandler | Downgrade | Neutral | $138← $315 |
| December 20th 2024 | BMO Capital Markets | Downgrade | Market Perform | $164← $230 |
| December 16th 2024 | Stifel | Downgrade | Hold | $175 |
| December 10th 2024 | BofA Securities | Resumed | Neutral | $178 |
| December 9th 2024 | Jefferies | Downgrade | Hold | $180← $250 |
| November 18th 2024 | Needham | Downgrade | Hold | - |
| November 15th 2024 | Wolfe Research | Initiation | Peer Perform | - |
| November 14th 2024 | Citigroup | Initiation | Neutral | $190 |
Earnings History & Surprises
BIIBEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 11, 2026 | $1.73 | — | — | — |
Q4 2025 | Oct 30, 2025 | $3.88 | $4.81 | +24.0% | ✓ BEAT |
Q3 2025 | Jul 31, 2025 | $3.90 | $5.47 | +40.3% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $2.90 | $3.02 | +4.1% | ✓ BEAT |
Q1 2025 | Feb 12, 2025 | $3.43 | $3.44 | +0.3% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | $3.77 | $4.08 | +8.2% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $4.07 | $5.28 | +29.7% | ✓ BEAT |
Q2 2024 | Apr 24, 2024 | $3.47 | $3.67 | +5.8% | ✓ BEAT |
Q1 2024 | Feb 13, 2024 | $3.16 | $2.95 | -6.6% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $3.99 | $4.36 | +9.3% | ✓ BEAT |
Q3 2023 | Jul 25, 2023 | $3.77 | $4.02 | +6.6% | ✓ BEAT |
Q2 2023 | Apr 25, 2023 | $3.28 | $3.40 | +3.7% | ✓ BEAT |
Q1 2023 | Feb 15, 2023 | $3.48 | $4.05 | +16.4% | ✓ BEAT |
Q4 2022 | Oct 25, 2022 | $4.13 | $4.77 | +15.5% | ✓ BEAT |
Q3 2022 | Jul 20, 2022 | $4.06 | $5.25 | +29.3% | ✓ BEAT |
Q2 2022 | May 3, 2022 | $4.41 | $3.62 | -17.9% | ✗ MISS |
Q1 2022 | Feb 3, 2022 | $3.32 | $3.39 | +2.1% | ✓ BEAT |
Q4 2021 | Oct 20, 2021 | $4.15 | $4.77 | +14.9% | ✓ BEAT |
Q3 2021 | Jul 22, 2021 | $4.57 | $5.68 | +24.3% | ✓ BEAT |
Latest News
Reported Friday, Nasdaq-100 Index Reconstituted As Alnylam, Ferrovial, Insmed, Monolithic Power, Seagate And Western Digital Join, While Biogen, CDW, GlobalFoundries, Lululemon, ON Semiconductor And Trade Desk Exit
➖ NeutralMorgan Stanley Maintains Equal-Weight on Biogen, Raises Price Target to $156
➖ NeutralBIIB stock has given up its prior loss. Biogen shares were trading lower after HSBC downgraded the stock from Hold to Reduce and lowered its price target from $144 to $143.
📉 NegativeWells Fargo Maintains Equal-Weight on Biogen, Raises Price Target to $190
➖ NeutralBiogen shares are trading lower after HSBC downgraded the stock from Hold to Reduce and lowered its price target from $144 to $143.
📉 NegativeHSBC Downgrades Biogen to Reduce, Lowers Price Target to $143
📉 NegativeReported Earlier, Eisai And Biogen Say LEQEMBI Added To China Commercial Insurance Innovative Drug List, Supporting Access For Early Alzheimer's Disease
📈 PositiveStoke Therapeutics And Biogen Present Data For Zorevunersen At 2025 American Epilepsy Society Annual Meeting in Atlanta, Georgia.
➖ NeutralBiogen And Eisai Present New CTAD Data Showing Lecanemab's Measurable CSF Binding To Aβ Protofibrils And Pharmacodynamic Effects That Support Its Dual Mechanism Slowing Alzheimer's Disease Progression
📈 PositiveBiogen And Stoke Therapeutics To Present Data From Studies Of Zorevunersen At 2025 AES Annual Meeting
➖ NeutralReported Earlier, Eisai And Biogen Announced That Eisai Has Filed A New Drug Application For "LEQEMBI" Seeking Approval For A Subcutaneous Formulation As A New Route Of Administration To Japan's Pharmaceuticals And Medical Devices Agency
📈 PositiveBiogen Announced That Its Partner Eisai Has Completed The Rolling Submission Of The Supplemental Biologics License Application To FDA For Leqembi (Lecanemab) Subcutaneous Autoinjector
📈 PositiveBiogen shares are trading higher after Novo Nordisk's Evoke Phase 3 trials did not show a statistically significant reduction in Alzheimer's disease progression.
📈 PositiveBiogen And Dayra Therapeutics Announce Research Collaboration To Discover And Develop Oral Macrocyclic Peptides For Priority Targets In Immunological Conditions
📈 PositivePiper Sandler Reiterates Neutral on Biogen, Raises Price Target to $157
➖ NeutralBiogen And Stoke Therapeutics Highlight Urgent Need For New Medicines Targeting Underlying Genetic Cause Of Dravet Syndrome To Improve Long Term Outcomes
➖ NeutralThe Committee For Medicinal Products For Human Use Of The European Medicines Agency Adopted A Positive Opinion Recommending The Approval Of Biogen's High-dose Regimen Of Nusinersen For 5q Spinal Muscular Atrophy. Final Decision Expected In January 2026
📈 PositiveReported Earlier, Eisai And Biogen Announce United Kingdom Approval Of LEQEMBI Lecanemab IV Maintenance Dosing For Early Alzheimer's Disease
📈 PositiveStifel Upgrades Biogen to Buy, Raises Price Target to $202
📈 PositiveBernstein Maintains Market Perform on Biogen, Raises Price Target to $157
➖ NeutralFrequently Asked Questions about BIIB
What is BIIB's current stock price?
What is the analyst price target for BIIB?
What sector is Biogen Inc. in?
What is BIIB's market cap?
Does BIIB pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BIIB for comparison